Pfizer raised its full-year profit forecast after strong second quarter results, driven by demand for heart disease drug Vyndaqel and blood thinner Eliquis. The drugmaker now expects to earn $2.90 to $3.10 per share in 2025 and saw shares rise 2.4% in premarket trading. The forecast includes a 20 cents per share impact from a recent licensing deal with China’s 3SBio for an experimental cancer treatment. Pfizer’s results come amid pressure to lower drug prices and potential tariffs on imports from the EU. The company reassured investors of its manufacturing capacity in the US to mitigate tariff impacts and is open to shifting production. Investors are also monitoring potential disruptions to Pfizer’s vaccine portfolio from policy changes under known vaccine skeptic RFK Jr. Vaccines make up about 20% of Pfizer’s revenues. On an adjusted basis, Pfizer earned 78 cents per share in the second quarter, beating analysts’ expectations of 58 cents per share.

Read more at Yahoo Finance: Pfizer raises annual profit forecast